Global Pharmacovigilance Market - Strategic Insights and Forecasts (2026-2031)

The global pharmacovigilance market is estimated at USD 7.80 billion in 2026 and is forecast to reach USD 12.70 billion in 2031, representing a CAGR of 10.24% over the forecast period.

These operating indicators support a global external-services market materially larger than simple per-case processing revenue. A complete pharmacovigilance program also requires medical assessment, expedited and periodic reporting, signal management, risk plans, literature surveillance, local affiliate coverage, database administration, quality systems, audits, and regulatory intelligence. Technology reduces manual effort in selected steps but does not eliminate the medical, compliance, and governance layers that account for a substantial share of spend.

The forecast assumes continued growth in marketed medicine portfolios, biologics and advanced therapies, more data from patient-support programs and digital channels, increasing regulatory expectations for near-real-time surveillance, and further transfer of safety operations to specialist providers. Growth is moderated by automation-led productivity gains, price pressure in commoditized case processing, sponsor consolidation, and the need to validate AI systems before they can be used in regulated decision-making.

Pharmacovigilance Market Trends

• AI Moves Into Governed Production Workflows

Pharmacovigilance providers are shifting AI from isolated pilots into controlled workflow components for intake, duplicate detection, data extraction, narrative support, literature screening, coding assistance, and signal analytics. The commercial effect is not simply lower headcount. Providers are increasingly selling a combination of safety expertise, automation, validation, audit trails, and human oversight. Parexel’s 2026 acquisition of Vitrana and PrimeVigilance’s deployment of Oracle Argus illustrate how service companies are integrating technology platforms directly into their operating models.

Regulatory acceptance remains risk-based rather than automatic. AI-supported work that influences safety decisions requires documented intended use, validation, quality controls, and traceability. This favors larger providers and specialists able to combine medical expertise with regulated technology implementation.

• Regulators Modernize Safety Data Infrastructure

The U.S. FDA began implementing the Adverse Event Monitoring System (AEMS) in March 2026 to consolidate previously separate adverse-event reporting systems and strengthen data quality, case processing, analytics, and cross-product surveillance. EMA has also been modernizing EudraVigilance analytics; its 2025 report states that a minimum viable product for Signal and Safety Analytics was deployed in December 2025 with additional enhancements planned in 2026.

These changes raise the technical bar for sponsors and service providers. Interfaces, E2B-compliant reporting, data quality, reconciliation, and inspection-ready evidence increasingly become part of the pharmacovigilance service proposition rather than back-office IT tasks.

• Post-Marketing Surveillance Becomes More Data Intensive

Safety monitoring is expanding beyond spontaneous adverse-event reports. Literature, registries, patient-support programs, digital engagement channels, real-world evidence, and product-specific risk-management commitments create more surveillance inputs. At the same time, specialty therapies and advanced modalities often have smaller trial populations and clinically complex risks, increasing the importance of medical review after launch.

This shifts value toward integrated teams that can combine high-volume operations with safety science. Providers that offer signal detection, epidemiology, benefit-risk assessment, risk-minimization support, and global affiliate coverage can capture work that is less exposed to unit-price competition than standard case entry.

• FSP and Full-Service Models Coexist

Sponsors increasingly use multiple outsourcing structures. Full-service pharmacovigilance transfers end-to-end responsibility to a provider, while functional service provider models supply dedicated teams embedded in sponsor processes and technology. Project-based consulting remains important for migrations, remediation, inspection readiness, and mergers or portfolio transfers.

The result is a market where scale and flexibility matter simultaneously. Large CROs can support multi-country portfolios and very high case volumes, while specialist pharmacovigilance firms compete on responsiveness, local coverage, medical depth, and safety-system expertise.

• Local Affiliate Coverage Remains Difficult to Automate Away

Country-level pharmacovigilance obligations continue to create demand for qualified-person, local responsible-person, literature, intelligence, and authority-contact services. Even where case processing is centralized, local reporting rules and inspection expectations can require in-country or region-specific expertise.

Global networks therefore remain commercially important. Providers are investing in affiliate models and partner networks across Latin America, Asia Pacific, Europe, and the Middle East to offer sponsors one governance layer across many national requirements.

Global Pharmacovigilance Market Segment Analysis

By Service Type

• ICSR Intake, Case Processing and Reporting

ICSR intake, case processing, medical coding, quality review, and regulatory submission are estimated to represent approximately 41.0% of the 2026 market, equivalent to about USD 3.20 billion. This remains the largest service pool because every clinical and marketed portfolio generates recurring safety cases with strict reporting timelines. Volume can be very large: Cognizant reports more than four million adverse-event case versions processed annually, while Fortrea reports more than one million ICSRs annually.

Automation is reducing manual touches per case, but expanding data sources and sponsor portfolios offset part of that productivity gain. The segment is therefore expected to grow below the overall market while remaining the largest revenue pool through 2031.

By Service Type

• Signal Detection, Benefit-Risk and Risk Management

Signal detection, safety surveillance, benefit-risk assessment, and risk-management support are estimated at approximately USD 1.33 billion in 2026, or about 17.0% of market revenue. This segment is expected to grow faster than routine case processing because regulators and sponsors are placing more emphasis on continuous signal evaluation across multiple data sources, not only individual spontaneous reports.

AI and advanced analytics increase the amount of information that can be screened, but clinically meaningful signal assessment remains dependent on medical and statistical judgment. That combination of technology and specialist expertise supports higher value per engagement and makes this one of the strongest growth areas within pharmacovigilance services.

By Product Lifecycle

• Post-Marketing Safety

Post-marketing pharmacovigilance is estimated at approximately USD 4.91 billion in 2026, representing about 63.0% of the total market. Once a product is marketed, obligations continue across spontaneous reporting, literature review, periodic reports, signal management, risk-management plans, labeling changes, local affiliate activities, and regulatory queries. Marketed portfolios also remain under surveillance for many years, creating a recurring installed base of work.

Pre-approval safety remains substantial, particularly for complex development programs, vaccines, oncology, rare disease, and advanced therapies, but the breadth and duration of post-marketing obligations keep commercialized products as the larger revenue pool.

By Delivery Model

• Full-Service and Managed Pharmacovigilance

Full-service and managed pharmacovigilance models are estimated at approximately USD 4.21 billion in 2026, or 54.0% of global market revenue. Sponsors use these models to transfer operational scale, global coverage, and technology responsibility while retaining governance and medical oversight. The model is particularly attractive to smaller biotechnology companies launching their first products and to large companies seeking to consolidate fragmented regional operations.

Functional service provider and staff-augmentation models remain important for sponsors that want greater control over processes and systems. Consulting and project work adds a smaller but higher-value layer around transformations, remediation, audits, and M&A integration.

By End User

• Pharmaceutical Companies

Pharmaceutical companies are estimated to account for approximately USD 5.38 billion of pharmacovigilance services revenue in 2026, or about 69.0% of the market. Large marketed portfolios, global authorization footprints, and continuous regulatory obligations make pharmaceutical companies the largest buyers. Biotechnology companies represent the fastest-expanding buyer group as emerging sponsors progress complex assets toward approval without building fully internal safety organizations.

Medical-device vigilance and consumer-health safety services are adjacent opportunities but are treated separately where regulatory frameworks and reporting systems materially differ from medicinal-product pharmacovigilance.

By Geography

• North America

North America is estimated at approximately USD 3.04 billion in 2026, representing about 39.0% of global market revenue. The United States combines the world’s largest pharmaceutical revenue pool, extensive clinical development, high outsourcing penetration, and demanding FDA post-marketing requirements. The FDA’s AEMS modernization also creates additional technology and data-integration work for sponsors and service providers.

Asia Pacific is expected to grow faster than North America through 2031. Growth is supported by expanding biopharmaceutical R&D, increasing local regulatory maturity, and the region’s role as a global delivery base for case processing, medical review, aggregate reporting, and safety technology operations.

Market Drivers

• Increasing Medicine Utilization and Product Complexity
  A larger and more complex portfolio of marketed medicines produces more safety data and more product-specific surveillance obligations. Biologics, oncology therapies, cell and gene therapies, and rare-disease products can require intensive medical assessment even where patient numbers are relatively small.

• Regulatory Reporting and Continuous Benefit-Risk Monitoring
  FDA, EMA, PMDA, MHRA, and other authorities require sponsors to maintain compliant pharmacovigilance systems, submit expedited and periodic reports, detect signals, and update risk-management measures. These are recurring legal obligations rather than discretionary analytics projects.

• Growth of Outsourcing and Functional Service Models
  Sponsors increasingly seek flexible capacity, 24-hour processing coverage, lower fixed infrastructure requirements, and access to country-specific expertise. Outsourcing is especially attractive during launches, acquisitions, portfolio transfers, and sudden case-volume increases.

• Expansion of Safety Data Sources
  Patient-support programs, literature, registries, digital channels, real-world evidence, and connected care generate additional safety information. More sources increase both intake workload and the need for deduplication, reconciliation, and advanced signal detection.

• Safety Technology Modernization
  Migration toward cloud safety databases, automated intake, analytics, and governed AI creates implementation, validation, integration, and managed-service demand in addition to traditional pharmacovigilance operations.

Market Restraints

• Automation and Pricing Pressure in Routine Case Processing
  Case intake and data-entry work is increasingly automated. Providers must convert productivity improvements into lower unit costs while protecting quality, which constrains revenue growth in the most standardized services.

• AI Validation and Regulatory Governance
  AI can accelerate safety workflows, but regulated use requires intended-use controls, validation, traceability, data-quality safeguards, and human oversight. Implementation can therefore be slower and more expensive than generic enterprise automation.

• Data Privacy and Cross-Border Constraints
  Safety cases can contain sensitive health and personal information. Global delivery models must address privacy laws, data residency, security, and contractual restrictions across jurisdictions.

• Fragmented Local Requirements
  Reporting timelines, local literature expectations, qualified-person requirements, and authority interfaces differ by market. This increases operating complexity and reduces the extent to which one global workflow can be standardized.

• Specialist Talent Requirements
  Medical review, signal assessment, benefit-risk evaluation, and inspection readiness require experienced safety physicians, pharmacists, scientists, and regulatory specialists. Shortages in these skills can constrain scaling and raise delivery costs.

Competitive Environment

The pharmacovigilance market combines large CROs, technology-enabled business-process providers, and specialist drug-safety firms. IQVIA, Parexel, ICON, Fortrea, Syneos Health, and the PPD clinical research business of Thermo Fisher Scientific compete with broad clinical-development relationships and global delivery scale. Cognizant and Indegene bring strong technology and process-transformation capabilities, while PrimeVigilance, ProPharma, APCER Life Sciences, ProductLife Group, PharmaLex, Navitas Life Sciences, ClinChoice, and Medpace compete through specialist safety operations, local coverage, consulting, and flexible service models.

Scale is most important in high-volume case operations, where utilization, automation, follow-the-sun delivery, and database expertise determine cost. Medical depth and regulatory credibility become more important in signal management, safety science, risk management, aggregate reporting, and inspection support. Providers are therefore investing in AI-enabled tools while retaining human medical review as the final control for high-impact decisions.

Technology ownership is becoming a differentiator. Parexel acquired Vitrana in April 2026 to add an AI-enabled end-to-end pharmacovigilance platform, while PrimeVigilance has integrated Oracle Argus into its service model. This does not eliminate specialist software vendors; instead, it shifts competition toward service providers capable of operating, validating, and improving safety technology as part of an outsourced program.

Recent Developments

• March 2026: The U.S. FDA moved FAERS data into the new Adverse Event Monitoring System (AEMS), part of a broader plan to consolidate adverse-event reporting systems and strengthen data quality, workflows, analytics, and cross-product surveillance.

• April 2026: Parexel announced the acquisition of Vitrana, adding an AI-enabled pharmacovigilance technology platform designed to integrate with major safety databases and automate end-to-end safety workflows.

• March 2026: EMA published its 2025 EudraVigilance annual report, reporting approximately 1.77 million ICSRs received in 2025 and noting deployment of a Signal and Safety Analytics minimum viable product in December 2025 with further enhancements expected during 2026.

• September 2025: PrimeVigilance acquired Prudentia Group, combining global pharmacovigilance operations with safety-technology, process, and management consulting capabilities.

• July 2025: PrimeVigilance expanded its technology-enabled drug-safety model using Oracle Argus, with an emphasis on AI-supported case management, workflow optimization, and regulatory compliance.

• 2025-2026: Major providers including IQVIA, ICON, Cognizant, Parexel, and Indegene increased emphasis on governed AI, automation, and advanced analytics across case intake, literature surveillance, signal management, and reporting.

Market Outlook

The pharmacovigilance market is expected to maintain high-single-digit to low-double-digit growth through 2031. Routine case processing will remain the largest service pool but will become more automated and price competitive. A greater share of incremental value is expected to come from safety science, signal analytics, global affiliate coverage, risk management, safety-system transformation, and technology-enabled managed services.

The strongest providers will combine three capabilities: global operational scale, medically credible safety expertise, and validated technology. Sponsors are unlikely to replace qualified safety judgment with autonomous AI, but they will increasingly expect providers to demonstrate measurable reductions in manual effort, faster cycle times, better data quality, and stronger oversight.

North America should remain the largest revenue market, while Asia Pacific gains share as a biopharmaceutical growth region and global delivery center. The forecast remains sensitive to pharmaceutical R&D cycles, provider pricing, sponsor consolidation, and the pace at which AI productivity is translated into lower service prices.

Global Pharmacovigilance Market Scope: